Alzheimer Disease (AD) is the most common form of dementia.1 There is currently no cure for the disease, and available treatments to relieve symptoms are moderately beneficial at best. The hallmark pathologic feature of AD involves the progressive accumulation of amyloid-β (Aβ) plaques and neurofibrillary tangles (NFTs) composed of hyperphosphorylated tau protein in the brain.2 Drug development for the prevention of AD has been hampered by the lack of fully validated biomarkers of early disease.
Ong SS, Doraiswamy PM, Lad EM. Controversies and Future Directions of Ocular Biomarkers in Alzheimer Disease. JAMA Neurol. Published online April 23, 2018. doi:10.1001/jamaneurol.2018.0602
Customize your JAMA Network experience by selecting one or more topics from the list below.